WO2024097944A2 - Dérivés de tryptamine - Google Patents

Dérivés de tryptamine Download PDF

Info

Publication number
WO2024097944A2
WO2024097944A2 PCT/US2023/078615 US2023078615W WO2024097944A2 WO 2024097944 A2 WO2024097944 A2 WO 2024097944A2 US 2023078615 W US2023078615 W US 2023078615W WO 2024097944 A2 WO2024097944 A2 WO 2024097944A2
Authority
WO
WIPO (PCT)
Prior art keywords
chloride
dpt
crystalline
crystalline form
purified
Prior art date
Application number
PCT/US2023/078615
Other languages
English (en)
Other versions
WO2024097944A3 (fr
Inventor
Andrew R. Chadeayne
Original Assignee
Caamtech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caamtech, Inc. filed Critical Caamtech, Inc.
Publication of WO2024097944A2 publication Critical patent/WO2024097944A2/fr
Publication of WO2024097944A3 publication Critical patent/WO2024097944A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin

Definitions

  • This disclosure relates to ⁇ 2-[4-(methanesulfonyloxy)-lH-indol-3-yl]ethyl ⁇ dipropylazanium chloride (4-(methylsulfonyloxy)-/V,A/-di-n-propyltryptammonium chloride or 4-(methylsulfonyloxy)- DPT chloride), crystalline 4-(methylsulfonyloxy)-DPT chloride, and specific crystalline forms thereof, including crystalline form 1 of 4-(methylsulfonyloxy)-DPT chloride; to pharmaceutical compositions containing 4-(methylsulfonyloxy)-DPT chloride or crystalline 4-(methylsulfonyloxy)-DPT chloride, including crystalline form 1 of 4-(methylsulfonyloxy)-DPT chloride; and to methods of treatment/therapeutic uses of 4-(methylsulfonyloxy)-DPT chloride or crystalline 4- (methylsulfony
  • This disclosure further relates to dipropyl(2- ⁇ 4-[4-(trifluoromethyl)benzoyloxy]-lH-indol-3- yl ⁇ ethyl)azanium chloride (4-(4-trifluoromethylbenzoyloxy)-A/,/V-di-n-propyltryptammonium chloride or 4-(4-trifluoromethylbenzoyloxy)-DPT chloride), crystalline 4-(4-trifluoromethylbenzoyloxy)-DPT chloride, and specific crystalline forms thereof, including crystalline form 1 of 4-(4- trifluoromethylbenzoyloxy)-DPT chloride; to pharmaceutical compositions containing 4-(4- trifluoromethylbenzoyloxy)-DPT chloride or crystalline 4-(4-trifluoromethylbenzoyloxy)-DPT chloride, including crystalline form 1 of 4-(4-trifluoromethylbenzoyloxy)-DPT chloride; and
  • This disclosure further relates to ⁇ 2-[4-(4-fluorobenzoyloxy)-lH-indol-3- yl]ethyl ⁇ dipropylazanium chloride (4-(4-fluorobenzoyloxy)-A/,A/-di-n-propyltryptammonium chloride or 4-(4-fluorobenzoyloxy)-DPT chloride), crystalline 4-(4-fluorobenzoyloxy)-DPT chloride, and specific crystalline forms thereof, including crystalline form 1 of 4-(4-fluorobenzoyloxy)-DPT chloride; to pharmaceutical compositions containing 4-(4-fluorobenzoyloxy)-DPT chloride or crystalline 4-(4- fluorobenzoyloxy)-DPT chloride, including crystalline form 1 of 4-(4-fluorobenzoyloxy)-DPT chloride; and to methods of treatment/therapeutic uses of 4-(4-fluorobenzoyloxy)-DPT chlor
  • This disclosure further relates to (2- ⁇ 4-[(2,2-dimethylpropanoyl)oxy]-lH-indol-3 yl ⁇ ethyl)dipropylazanium chloride (4-pivaloyloxy-/V,A/-di-n-propyltryptammonium chloride or 4-PivO- DPT chloride), crystalline 4-PivO-DPT chloride, and specific crystalline forms thereof, including crystalline form 1 of 4-PivO-DPT chloride; to pharmaceutical compositions containing 4-PivO-DPT chloride or crystalline 4-PivO-DPT chloride, including crystalline form 1 of 4-PivO-DPT chloride; and to methods of treatment/therapeutic uses of 4-PivO-DPT chloride or crystalline 4-PivO-DPT chloride, including crystalline form 1 of 4-PivO-DPT chloride.
  • This disclosure further relates to dimethyl( ⁇ 2-[4-(propanoyloxy)-lH-indol-3-yl]ethyl ⁇ )azanium (2E)-3-carboxyprop-2-enoate (4-propanoyloxy-/V,A/-dimethyltryptammonium hydrofumarate or 4- Pro-DMT hydrofumarate), crystalline 4-Pro-DMT hydrofumarate, and specific crystalline forms thereof, including crystalline form 1 of 4-Pro-DMT hydrofumarate; to pharmaceutical compositions containing 4-Pro-DMT hydrofumarate or crystalline 4-Pro-DMT hydrofumarate, including crystalline form 1 of 4-Pro-DMT hydrofumarate; and to methods of treatment/therapeutic uses of 4-Pro-DMT hydrofumarate or crystalline 4-Pro-DMT hydrofumarate, including crystalline form 1 of 4-Pro-DMT hydrofumarate.
  • This disclosure further relates to (2- ⁇ 4-[(4-nitrobenzenesulfonyl)oxy]-lH-indol-3- yl ⁇ ethyl)dipropylazanium chloride hydrate (4-[(4-nitrophenyl)sulfonyloxy]-A/,A/-di-n- propyltryptammonium chloride hydrate or 4-[(4-nitrophenyl)sulfonyloxy]-DPT chloride hydrate), crystalline 4-[(4-nitrophenyl)sulfonyloxy]-DPT chloride hydrate, and specific crystalline forms thereof, including crystalline form 1 of 4-[(4-nitrophenyl)sulfonyloxy]-DPT chloride hydrate; to pharmaceutical compositions containing 4-[(4-nitrophenyl)sulfonyloxy]-DPT chloride hydrate or crystalline 4-[(4-nitrophenyl)sulfonyloxy]-DPT
  • Obtaining specific salts or crystalline forms of an active pharmaceutical ingredient (API) is extremely useful in drug development. It permits better characterization of the drug candidate's chemical and physical properties. Crystalline forms often have better chemical and physical properties than the API in its amorphous state. Such crystalline forms may possess more favorable pharmaceutical and pharmacological properties or be easier to process. Additionally, preparing a crystalline API and solving its crystal structure provides the gold standard for chemical characterization and determining the molecular formula (and molecular weight) of the API. Accordingly, preparing a crystalline form with an accompanying crystal structure thereof prevents potential ambiguities and/or inaccuracies in the API's molecular weight.
  • API's molecular weight is used to calculate the concentration of compositions comprising that API.
  • inaccuracies in molecular weight may lead to errors in the calculations pertaining to dosing, potency, toxicity, etc. in all downstream in vitro and in vivo assays that correlated the concentration of the API with a measured property. Accordingly, there remains a need to obtain and characterize crystalline forms of APIs, such as tryptamines and other psychedelic drug compounds.
  • This disclosure relates to ⁇ 2-[4-(methanesulfonyloxy)-lH-indol-3-yl]ethyl ⁇ dipropylazanium chloride (4-(methylsulfonyloxy)-N,N-di-n-propyltryptammonium chloride or 4-(methylsulfonyloxy)- DPT chloride), crystalline 4-(methylsulfonyloxy)-DPT chloride, and specific crystalline forms thereof.
  • this disclosure pertains to particular crystalline forms of 4-(methylsulfonyloxy)- DPT chloride, including crystalline form 1 of 4-(methylsulfonyloxy)-DPT chloride.
  • XRPD X-ray powder diffraction
  • This disclosure further relates to dipropyl(2- ⁇ 4-[4-(trifluoromethyl)benzoyloxy]-lH- indol-3-yl ⁇ ethyl)azanium chloride (4-(4-trifluoromethylbenzoyloxy)-N,N-di-n-propyltryptam monium chloride or 4-(4-trifluoromethylbenzoyloxy)-DPT chloride), crystalline 4-(4- trifluoromethylbenzoyloxy)-DPT chloride, and specific crystalline forms thereof.
  • this disclosure pertains to particular crystalline forms of 4-(4-trifluoromethylbenzoyloxy)-DPT chloride, including crystalline form 1 of 4-(4-trifluoromethylbenzoyloxy)-DPT chloride.
  • XRPD X-ray powder diffraction
  • This disclosure further relates to ⁇ 2-[4-(4-fluorobenzoyloxy)-lH-indol-3- yl]ethyl ⁇ dipropylazanium chloride (4-(4-fluorobenzoyloxy)-N,N-di-n-propyltryptammonium chloride or 4-(4-fluorobenzoyloxy)-DPT chloride), crystalline 4-(4-fluorobenzoyloxy)-DPT chloride, and specific crystalline forms thereof.
  • this disclosure pertains to particular crystalline forms of 4-(4-fluorobenzoyloxy)-DPT chloride, including crystalline form 1 of 4-(4-fluorobenzoyloxy)-DPT chloride.
  • XRPD X-ray powder diffraction
  • This disclosure further relates to (2- ⁇ 4-[(2,2-dimethylpropanoyl)oxy]-lH-indol-3 yl ⁇ ethyl)dipropylazanium chloride (4-pivaloyloxy-N,N-di-n-propyltryptammonium chloride or 4-PivO- DPT chloride), crystalline 4-PivO-DPT chloride, and specific crystalline forms thereof.
  • this disclosure pertains to particular crystalline forms of 4-PivO-DPT chloride, including crystalline form 1 of 4-PivO-DPT chloride.
  • XRPD X-ray powder diffraction
  • This disclosure further relates to dimethyl( ⁇ 2-[4-(propanoyloxy)-lH-indol-3- yl]ethyl ⁇ )azanium (2E)-3-carboxyprop-2-enoate (4-propanoyloxy-A/,A/-dimethyltryptammonium hydrofumarate or 4-Pro-DMT hydrofumarate), crystalline 4-Pro-DMT hydrofumarate, and specific crystalline forms thereof.
  • this disclosure pertains to particular crystalline forms of 4-Pro-DMT hydrofumarate, including crystalline form 1 of 4-Pro-DMT hydrofumarate.
  • XRPD X-ray powder diffraction
  • This disclosure further relates to (2- ⁇ 4-[(4-nitrobenzenesulfonyl)oxy]-lH-indol-3- yl ⁇ ethyl)dipropylazanium chloride hydrate (4-[(4-nitrophenyl)sulfonyloxy]-N,N-di-n- propyltryptammonium chloride hydrate or 4-[(4-nitrophenyl)sulfonyloxy]-DPT chloride hydrate), crystalline 4-[(4-nitrophenyl)sulfonyloxy]-DPT chloride hydrate, and specific crystalline forms thereof.
  • this disclosure pertains to particular crystalline forms of 4-[(4- nitrophenyl)sulfonyloxy]-DPT chloride hydrate, including crystalline form 1 of 4-[(4- nitrophenyl)sulfonyloxy]-DPT chloride hydrate.
  • XRPD X-ray powder diffraction
  • the disclosure further relates to a composition comprising 4-(methylsulfonyloxy)-
  • DPT chloride crystalline 4-(methylsulfonyloxy)-DPT chloride, or specific crystalline forms thereof, such as crystalline form 1 of 4-(methylsulfonyloxy)-DPT chloride, and at least one excipient.
  • the disclosure further relates to a composition
  • a composition comprising 4-(4- trifluoromethylbenzoyloxy)-DPT chloride, crystalline 4-(4-trifluoromethylbenzoyloxy)-DPT chloride, or specific crystalline forms thereof, such as crystalline form 1 of 4-(4-trifluoromethylbenzoyloxy)- DPT chloride, and at least one excipient.
  • the disclosure further relates to a composition comprising 4-(4-fluorobenzoyloxy)-
  • DPT chloride crystalline 4-(4-fluorobenzoyloxy)-DPT chloride, or specific crystalline forms thereof, such as crystalline form 1 of 4-(4-fluorobenzoyloxy)-DPT chloride, and at least one excipient.
  • the disclosure further relates to a composition
  • a composition comprising 4-PivO-DPT chloride, crystalline 4-PivO-DPT chloride, or specific crystalline forms thereof, such as crystalline form 1 of 4- PivO-DPT chloride, and at least one excipient.
  • the disclosure further relates to a composition
  • a composition comprising 4-Pro-DMT hydrofumarate, crystalline 4-Pro-DMT hydrofumarate, or specific crystalline forms thereof, such as crystalline form 1 of 4-Pro-DMT hydrofumarate, and at least one excipient.
  • the disclosure further relates to a composition
  • a composition comprising 4-[(4- nitrophenyl)sulfonyloxy]-DPT chloride hydrate, crystalline 4-[(4-nitrophenyl)sulfonyloxy]-DPT chloride hydrate, or specific crystalline forms thereof, such as crystalline form 1 of 4-[ (4- nitrophenyl)sulfonyloxy]-DPT chloride hydrate, and at least one excipient.
  • the disclosure also provides a composition comprising 4-(methylsulfonyloxy)-DPT chloride, crystalline 4-(methylsulfonyloxy)-DPT chloride, 4-(4-trifluoromethylbenzoyloxy)-DPT chloride, crystalline 4-(4-trifluoromethylbenzoyloxy)-DPT chloride, 4-(4-fluorobenzoyloxy)-DPT chloride, crystalline 4-(4-fluorobenzoyloxy)-DPT chloride, 4-PivO-DPT chloride, crystalline 4-PivO-DPT chloride, 4-Pro-DMT hydrofumarate, crystalline 4-Pro-DMT hydrofumarate, 4-[(4- nitrophenyl)sulfonyloxy]-DPT chloride hydrate, crystalline 4-[(4-nitrophenyl)sulfonyloxy]-DPT chloride hydrate, or specific crystalline forms thereof, such as crystalline form 1 of 4- (methylsulfon)-D
  • the disclosure also relates to a method of preventing or treating a psychological disorder comprising the step of administering to a subject in need thereof a therapeutically effective amount of 4-(methylsulfonyloxy)-DPT chloride, crystalline 4-(methylsulfonyloxy)-DPT chloride, 4-(4- trifluoromethylbenzoyloxy)-DPT chloride, crystalline 4-(4-trifluoromethylbenzoyloxy)-DPT chloride, 4-(4-fluorobenzoyloxy)-DPT chloride, crystalline 4-(4-fluorobenzoyloxy)-DPT chloride, 4-PivO-DPT chloride, crystalline 4-PivO-DPT chloride, 4-Pro-DMT hydrofumarate, crystalline 4-Pro-DMT hydrofumarate, 4-[(4-nitrophenyl)sulfonyloxy]-DPT chloride hydrate, crystalline 4-[(4-nitrophenyl)sulfonyloxy]-DPT
  • the disclosure further relates to a method of preventing or treating inflammation and/or pain, preventing or treating a neurological disorder, modulating activity of a mitogen- activated protein kinase (MAPK), modulating neurogenesis, or modulating neurite outgrowth comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of 4-(methylsulfonyloxy)-DPT chloride, crystalline 4-(methylsulfonyloxy)-DPT chloride, 4-(4-trifluoromethylbenzoyloxy)-DPT chloride, crystalline 4-(4-trifluoromethylbenzoyloxy)- DPT chloride, 4-(4-fluorobenzoyloxy)-DPT chloride, crystalline 4-(4-fluorobenzoyloxy)-DPT chloride, 4-PivO-DPT chloride, crystalline 4-PivO-DPT chloride, 4-Pro-DMT hydrofumarate, crystalline 4-Pro- DMT hydrofuma
  • a subject in need thereof refers to a person requiring a composition to treat a particular disease or condition (e.g., inflammation, pain, a psychological disorder, modulating activity at a receptor, etc.).
  • the "subject in need thereof” may be identified by analyzing, diagnosing, and/or determining whether the person (or subject) requires the composition for treatment of a particular disease or condition.
  • identifying a person in need of treatment comprises diagnosing a person with a medical condition, e.g., a neurological disorder, a chemical imbalance, a hereditary condition, etc.
  • identifying a person in need of treatment comprises performing a psychiatric evaluation.
  • identifying a person in need of treatment comprises performing a blood test. In one embodiment, identifying a person in need of treatment comprises determining whether a person has a compulsive disorder. In one embodiment, identifying a person in need of treatment comprises self-identifying as having a compulsive disorder.
  • FIG. 1 shows the molecular structure of crystalline form 1 of 4-(methylsulfonyloxy)-
  • FIG. 2 shows the molecular structure of crystalline form 1 of 4-(4- trifluoromethylbenzoyloxy)-N,N-di-n-propyltryptammonium chloride.
  • FIG. 3 shows the molecular structure of crystalline form 1 of 4-(4-fluorobenzoyloxy)-
  • FIG. 4 shows the molecular structure of crystalline form 1 of 4-pivaloyloxy-N,N-di-n- propyltryptammonium chloride.
  • FIG. 5 shows the molecular structure of crystalline form 1 of 4-propanoyloxy-/V,/V- dimethyltryptammonium hydrofumarate.
  • FIG. 6 shows the molecular structure of crystalline form 1 of 4-[(4- nitrophenyl)sulfonyloxy]-N,N-di-n-propyltryptammonium chloride hydrate.
  • FIG. 7 shows the unit cell of crystalline form 1 of 4-(methylsulfonyloxy)-N,N-di-n- propyltryptammonium chloride along the a-axis.
  • FIG. 8 shows the unit cell of crystalline form 1 of 4-(4-trifluoromethylbenzoyloxy)-
  • N,N-di-n-propyltryptammonium chloride along the b-axis.
  • FIG. 9 shows the unit cell of crystalline form 1 of 4-(4-fluorobenzoyloxy)-N,N-di-n- propyltryptammonium chloride along the b-axis.
  • FIG. 10 shows the unit cell of crystalline form 1 of 4-pivaloyloxy-N,N-di-n- propyltryptammonium chloride along the a-axis.
  • FIG. 11 shows the unit cell of crystalline form 1 of 4-propanoyloxy-A/,/V- dimethyltryptammonium hydrofumarate along the b-axis.
  • FIG. 12 shows the unit cell of crystalline form 1 of 4-[(4-nitrophenyl)sulfonyloxy]-
  • N,N-di-n-propyltryptammonium chloride hydrate along the a-axis.
  • FIG. 13 shows the simulated X-ray powder diffraction pattern (XRPD) for crystalline form 1 of 4-(methylsulfonyloxy)-N,N-di-n-propyltryptammonium chloride.
  • FIG. 14 shows the simulated X-ray powder diffraction pattern (XRPD) for crystalline form 1 of 4-(4-trifluoromethylbenzoyloxy)-N,N-di-n-propyltryptammonium chloride.
  • FIG. 15 shows the simulated X-ray powder diffraction pattern (XRPD) for crystalline form 1 of 4-(4-fluorobenzoyloxy)-N,N-di-n-propyltryptammonium chloride.
  • FIG. 16 shows the simulated X-ray powder diffraction pattern (XRPD) for crystalline form 1 of 4-pivaloyloxy-N,N-di-n-propyltryptammonium chloride.
  • FIG. 17 shows the simulated X-ray powder diffraction pattern (XRPD) for crystalline form 1 of 4-propanoyloxy-A/,/V-dimethyltryptammonium hydrofumarate.
  • FIG. 18 shows the simulated X-ray powder diffraction pattern (XRPD) for crystalline form 1 of 4-[(4-nitrophenyl)sulfonyloxy]-N,N-di-n-propyltryptammonium chloride hydrate.
  • This disclosure relates to ⁇ 2-[4-(methanesulfonyloxy)-lH-indol-3- yl]ethyl ⁇ dipropylazanium chloride (4-(methylsulfonyloxy)-N,N-di-n-propyltryptammonium chloride or 4-(methylsulfonyloxy)-DPT chloride), crystalline 4-(methylsulfonyloxy)-DPT chloride, dipropyl(2- ⁇ 4-[4- (trifluoromethyl)benzoyloxy]-lH-indol-3-yl ⁇ ethyl)azanium chloride (4-(4-trifluoromethylbenzoyloxy)- N,N-di-n-propyltryptammonium chloride or 4-(4-trifluoromethylbenzoyloxy)-DPT chloride), crystalline 4-(4-trifluoromethylbenzoyloxy)-DPT chloride,
  • 4-PivO-DPT chloride has the following chemical formula:
  • 4-Pro-DMT hydrofumarate has the following chemical formula:
  • Methods of the disclosure also relate to the administration of a therapeutically effective amount of 4-(methylsulfonyloxy)-DPT chloride, crystalline 4-(methylsulfonyloxy)-DPT chloride, 4-(4-trifluoromethylbenzoyloxy)-DPT chloride, crystalline 4-(4-trifluoromethylbenzoyloxy)- DPT chloride, 4-(4-fluorobenzoyloxy)-DPT chloride, crystalline 4-(4-fluorobenzoyloxy)-DPT chloride, 4-PivO-DPT chloride, crystalline 4-PivO-DPT chloride, 4-Pro-DMT hydrofumarate, crystalline 4-Pro- DMT hydrofumarate, 4-[(4-nitrophenyl)sulfonyloxy]-DPT chloride hydrate, crystalline 4-[(4- nitrophenyl)sulfonyloxy]-DPT chloride hydrate, or specific crystalline forms thereof, such as crystalline form
  • the disclosure provides a method for preventing and/or treating a psychological disorder by administering to a subject in need thereof a therapeutically effective amount of 4-(methylsulfonyloxy)-DPT chloride, crystalline 4- (methylsulfonyloxy)-DPT chloride, 4-(4-trifluoromethylbenzoyloxy)-DPT chloride, crystalline 4-(4- trifluoromethylbenzoyloxy)-DPT chloride, 4-(4-fluorobenzoyloxy)-DPT chloride, crystalline 4-(4- fluorobenzoyloxy)-DPT chloride, 4-PivO-DPT chloride, crystalline 4-PivO-DPT chloride, 4-Pro-DMT hydrofumarate, crystalline 4-Pro-DMT hydrofumarate, 4-[(4-nitrophenyl)sulfonyloxy]-DPT chloride hydrate, crystalline 4-[(4-nitrophenyl)sulfonyloxy]-DPT chloride hydrate,
  • the psychological disorder may be chosen from: depression; psychotic disorder; schizophrenia; schizophreniform disorder (acute schizophrenic episode); schizoaffective disorder; bipolar I disorder (mania, manic disorder, manic-depressive psychosis); bipolar II disorder; major depressive disorder; major depressive disorder with psychotic feature (psychotic depression); delusional disorders (paranoia); shared psychotic disorder (shared paranoia disorder); brief psychotic disorder (other and unspecified reactive psychosis); psychotic disorder not otherwise specified (unspecified psychosis); paranoid personality disorder; schizoid personality disorder; schizotypal personality disorder; anxiety disorder; social anxiety disorder; substance-induced anxiety disorder; selective mutism; panic disorder; panic attacks; agoraphobia; attention deficit syndrome; post-traumatic stress disorder (PTSD); premenstrual dysphoric disorder (PMDD); and premenstrual syndrome (PMS).
  • depression depression
  • psychotic disorder schizophrenia
  • schizophreniform disorder acute schizophrenic episode
  • the disclosure provides a method for preventing and/or treating a brain disorder (e.g., Huntington's disease, Alzheimer's disease, dementia, and Parkinson's disease) by administering to a subject in need thereof a therapeutically effective amount of 4-(methylsulfonyloxy)-DPT chloride, crystalline 4-(methylsulfonyloxy)-DPT chloride, 4-(4- trifluoromethylbenzoyloxy)-DPT chloride, crystalline 4-(4-trifluoromethylbenzoyloxy)-DPT chloride, 4-(4-fluorobenzoyloxy)-DPT chloride, crystalline 4-(4-fluorobenzoyloxy)-DPT chloride, 4-PivO-DPT chloride, crystalline 4-PivO-DPT chloride, 4-Pro-DMT hydrofumarate, crystalline 4-Pro-DMT hydrofumarate, 4-[(4-nitrophenyl)sulfonyloxy]-DPT chloride hydrate, crystalline 4-
  • the disclosure provides a method for preventing and/or treating these disorders by administering to a subject in need thereof a therapeutically effective amount of 4-(methylsulfonyloxy)-DPT chloride, crystalline 4- (methylsulfonyloxy)-DPT chloride, 4-(4-trifluoromethylbenzoyloxy)-DPT chloride, crystalline 4-(4- trifluoromethylbenzoyloxy)-DPT chloride, 4-(4-fluorobenzoyloxy)-DPT chloride, crystalline 4-(4- fluorobenzoyloxy)-DPT chloride, 4-PivO-DPT chloride, crystalline 4-PivO-DPT chloride, 4-Pro-DMT hydrofumarate, crystalline 4-Pro-DMT hydrofumarate, 4-[(4-nitrophenyl)sulfonyloxy]-DPT chloride hydrate, crystalline 4-[(4-nitrophenyl)sulfonyloxy]-DPT chloride hydrate, or specific
  • the disclosure provides a method for preventing and/or treating an inflammation and/or pain by administering to a subject in need thereof a therapeutically effective amount of 4-(methylsulfonyloxy)-DPT chloride, crystalline 4-(methylsulfonyloxy)-DPT chloride, 4-(4-trifluoromethylbenzoyloxy)-DPT chloride, crystalline 4-(4-trifluoromethylbenzoyloxy)-DPT chloride, 4-(4-fluorobenzoyloxy)-DPT chloride, crystalline 4-(4-fluorobenzoyloxy)-DPT chloride, 4-PivO-DPT chloride, crystalline 4-PivO-DPT chloride, 4-Pro-DMT hydrofumarate, crystalline 4-Pro-DMT hydrofumarate, 4-[(4-nitrophenyl)sulfonyloxy]- DPT chloride hydrate, crystalline 4-[(4-nitrophenyl)sulfonyloxy]-DPT chloride
  • treatable "pain” includes nociceptive, neuropathic, and mix-type.
  • a method of the disclosure may reduce or alleviate the symptoms associated with inflammation, including but not limited to treating localized manifestation of inflammation characterized by acute or chronic swelling, pain, redness, increased temperature, or loss of function in some cases.
  • a method of the disclosure may reduce or alleviate the symptoms of pain regardless of the cause of the pain, including but not limited to reducing pain of varying severity, i.e., mild, moderate and severe pain, acute pain and chronic pain.
  • a method of the disclosure is effective in treating joint pain, muscle pain, tendon pain, burn pain, and pain caused by inflammation such as rheumatoid arthritis.
  • Skeletal or muscular diseases or conditions which may be treated include but are not limited to musculoskeletal sprains, musculoskeletal strains, tendinopathy, peripheral radiculopathy, osteoarthritis, joint degenerative disease, polymyalgia rheumatica, juvenile arthritis, gout, ankylosing spondylitis, psoriatic arthritis, systemic lupus erythematosus, costochondritis, tendonitis, bursitis, such as the common lateral epicondylitis (tennis elbow), medial epicondylitis (pitchers elbow) and trochanteric bursitis, temporomandibular joint syndrome, and fibromyalgia.
  • MAPKs provide a wide-ranging signaling cascade that allow cells to quickly respond to biotic and abiotic stimuli.
  • exemplary MAPKs include, but are not limited to, Tropomyosin Receptor Kinase A (TrkA), P38-alpha, and c-Jun N-Terminal Kinase 3 (JNK3).
  • TrkA is a high affinity catalytic receptor of nerve growth factor (NGF) protein. TrkA regulates NGF response, influencing neuronal differentiation and outgrowth as well as programmed cell death.
  • NGF nerve growth factor
  • p38-alpha is involved with the regulation of pro-inflammatory cytokines, including TNF-a. In the central nervous
  • JNK3 is a neuronal-specific protein isoform of the JNKs. It is involved with the regulation of apoptosis. JNK3 also plays a role in modulating the response of cytokines, growth factors, and oxidative stress.
  • modulating activity of a mitogen-activated protein kinase refers to changing, manipulating, and/or adjusting the activity of a mitogen-activated protein kinase.
  • modulating the activity of a MAPK can influence neural health, neurogenesis, neural growth and differentiation, and neurodegenerative diseases.
  • neurogenesis refers to changing, manipulating, and/or adjusting the growth and development of neural tissue.
  • neurogenesis comprises adult neurogenesis, in which new neural stem cells are generated from neural stem cells in an adult animal.
  • modulating neurogenesis comprises increasing and/or enhancing the rate at which new neural tissue is developed.
  • modulating neurite outgrowth refers to changing, manipulating, and/or adjusting the growth and development of neural projections, or "neurites.”
  • neurogenesis comprises modulating the growth of new neurites, the number of neurites per neuron, and/or neurite length.
  • modulating neurite outgrowth comprises increasing and/or enhancing the rate and/or length at which neurites develop.
  • compositions comprising an effective amount of 4-
  • the disclosure also relates to pharmaceutical compositions comprising a therapeutically effective amount of 4- (methylsulfonyloxy)-DPT chloride, crystalline 4-(methylsulfonyloxy)-DPT chloride, 4-(4- trifluoromethylbenzoyloxy)-DPT chloride, crystalline 4-(4-trifluoromethylbenzoyloxy)-DPT chloride, 4-(4-fluorobenzoyloxy)-DPT chloride, crystalline 4-(4-fluorobenzoyloxy)-DPT chloride, 4-PivO-DPT chloride, crystalline 4-PivO-DPT chloride, 4-Pro-DMT hydrofumarate, crystalline 4-Pro-DMT hydrofumarate, 4-[(4-nitrophenyl)sulfonyloxy]-DPT chloride hydrate, crystalline 4-[(4- nitrophenyl)sulfonyloxy]-DPT chloride hydrate, or specific crystalline forms thereof, such as crystalline form
  • a composition or a pharmaceutical composition of the disclosure may be in any form which contains 4-(methylsulfonyloxy)-DPT chloride, crystalline 4-(methylsulfonyloxy)-DPT chloride, 4-(4-trifluoromethylbenzoyloxy)-DPT chloride, crystalline 4-(4-trifluoromethylbenzoyloxy)-DPT chloride, 4-(4-fluorobenzoyloxy)-DPT chloride, crystalline 4-(4-fluorobenzoyloxy)-DPT chloride, 4- PivO-DPT chloride, crystalline 4-PivO-DPT chloride, 4-Pro-DMT hydrofumarate, crystalline 4-Pro-DMT hydrofumarate, 4-[(4-nitrophenyl)sulfonyloxy]-DPT chloride hydrate, crystalline 4-[(4- nitrophenyl)sulfonyloxy]-DPT chloride hydrate, or specific crystalline forms thereof, such as crystalline form 1 of
  • the composition may be, for example, a tablet, capsule, liquid suspension, injectable, topical, or transdermal.
  • the compositions generally contain, for example, about 1% to about 99% by weight of 4- (methylsulfonyloxy)-DPT chloride, crystalline 4-(methylsulfonyloxy)-DPT chloride, 4-(4- trifluoromethylbenzoyloxy)-DPT chloride, crystalline 4-(4-trifluoromethylbenzoyloxy)-DPT chloride, 4-(4-fluorobenzoyloxy)-DPT chloride, crystalline 4-(4-fluorobenzoyloxy)-DPT chloride, 4-PivO-DPT chloride, crystalline 4-PivO-DPT chloride, 4-Pro-DMT hydrofumarate, crystalline 4-Pro-DMT hydrofumarate, 4-[(4-nitrophenyl)sulfonyloxy]-DPT chloride hydrate, crystalline 4-[(4-nitrophenyl)s
  • the composition may be between about 5% and about 75% by weight of 4- (methylsulfonyloxy)-DPT chloride, crystalline 4-(methylsulfonyloxy)-DPT chloride, 4-(4- trifluoromethylbenzoyloxy)-DPT chloride, crystalline 4-(4-trifluoromethylbenzoyloxy)-DPT chloride, 4-(4-fluorobenzoyloxy)-DPT chloride, crystalline 4-(4-fluorobenzoyloxy)-DPT chloride, 4-PivO-DPT chloride, crystalline 4-PivO-DPT chloride, 4-Pro-DMT hydrofumarate, crystalline 4-Pro-DMT hydrofumarate, 4-[(4-nitrophenyl)sulfonyloxy]-DPT chloride hydrate, crystalline 4-[(4- nitrophenyl)sulfonyloxy]-DPT chloride hydrate, or specific crystalline forms thereof, such as crystalline form 1 of 4-
  • compositions comprising a combination of a first purified psilocybin derivative with a second purified psilocybin derivative, with one or two purified cannabinoids or with a purified terpene. Various ratios of these components in the composition are also disclosed.
  • the disclosures of US 2018/0221396 Al and US 2019/0142851 Al are incorporated herein by reference.
  • this disclosure provides a composition
  • a composition comprising: a first component comprising 4-(methylsulfonyloxy)-DPT chloride, crystalline 4-(methylsulfonyloxy)-DPT chloride, 4-(4-trifluoromethylbenzoyloxy)-DPT chloride, crystalline 4-(4-trifluoromethylbenzoyloxy)- DPT chloride, 4-(4-fluorobenzoyloxy)-DPT chloride, crystalline 4-(4-fluorobenzoyloxy)-DPT chloride, 4-PivO-DPT chloride, crystalline 4-PivO-DPT chloride, 4-Pro-DMT hydrofumarate, crystalline 4-Pro- DMT hydrofumarate, 4-[(4-nitrophenyl)sulfonyloxy]-DPT chloride hydrate, crystalline 4-[(4- nitrophenyl)sulfonyloxy]-DPT chloride hydrate, or specific crystalline forms thereof, such as crystalline form 1
  • compositions having as a first component 4- (methylsulfonyloxy)-DPT chloride, crystalline 4-(methylsulfonyloxy)-DPT chloride, 4-(4- trifluoromethylbenzoyloxy)-DPT chloride, crystalline 4-(4-trifluoromethylbenzoyloxy)-DPT chloride, 4-(4-fluorobenzoyloxy)-DPT chloride, crystalline 4-(4-fluorobenzoyloxy)-DPT chloride, 4-PivO-DPT chloride, crystalline 4-PivO-DPT chloride, 4-Pro-DMT hydrofumarate, crystalline 4-Pro-DMT hydrofumarate, 4-[(4-nitrophenyl)sulfonyloxy]-DPT chloride hydrate, crystalline 4-[(4- nitrophenyl)sulfonyloxy]-DPT chloride hydrate, or specific crystalline forms thereof, such as crystalline form 1 of 4-(methylsulfonyloxy)
  • the first and second components can be administered at the same time (e.g., together in the same composition), or at separate times over the course of treating a patient in need thereof.
  • a composition may be a pharmaceutical composition wherein the components are present individually in therapeutically effective amounts or by combination in a therapeutically effective amount to treat a disease, disorder, or condition as described herein.
  • the term “purified” means separated from other materials, such as plant or fungal material, e.g., protein, chitin, cellulose, or water.
  • the term “purified” refers to a compound substantially free of other materials.
  • the term “purified” refers to a compound that is substantially free from a second tryptamine compound.
  • the term “purified” refers to a compound substantially free from histidine.
  • the term “purified” refers to a compound substantially free from a biological material, such as mold, fungus, plant matter, or bacteria.
  • the term “purified” refers to a compound substantially free from a paralytic.
  • the term "purified” refers to a compound which has been separated from other compounds that are typically co-extracted when the purified compound is extracted from a naturally occurring organism.
  • a "purified" psilocybin derivative is partially or completely isolated from other psilocybin derivatives present in a source material, such as a psilocybin-containing mushroom.
  • "purified" baeocystin is substantially free from psilocybin and/or psilocin.
  • psilocybin mushroom extracts aka crude extracts or fruit body extracts
  • traditional psilocybin mushroom extracts would be expected to contain an unpredictable and varying amount of psilocybin, psilocin, baeocystin, norbaeocystin, salts thereof, or combinations thereof.
  • unpurified psilocybin derivatives would include mycelium containing psilocybin derivatives and/or naturally occurring fungal material such as biological material and/or structural material such as chitin.
  • cannabidiol cannabidiol
  • CBD cannabidiol
  • the term "purified" refers to a compound or composition that has been crystallized.
  • the term "purified" refers to a compound or composition that has been chromatographed, for example by gas chromatography, liquid chromatography (e.g., LC, HPLC, etc.), etc.
  • the term "purified" refers to a compound or composition that has been distilled.
  • the term "purified" refers to a compound or composition that has been sublimed.
  • the term "purified" refers to a compound or composition that has been subject to two or more steps chosen from crystallization, chromatography, distillation, or sublimation.
  • the term "purified" refers to a compound that is between 80-
  • the term “purified” refers to a compound that is between 90-
  • the term “purified” refers to a compound that is between 95-
  • the term “purified” refers to a compound that is between 99-
  • the term "purified" refers to a compound that is between 99.9-
  • a serotonergic drug refers to a compound that binds to, blocks, or otherwise influences (e.g., via an allosteric reaction) activity at a serotonin receptor as described in paragraphs [0245]-[0253] of US 2018/0221396 Al and [0305]-[0311] US 2019/0142851 Al as well as the disclosed exemplary embodiments.
  • Exemplary psilocybin derivatives include but are not limited to psilocybin itself and the psilocybin derivatives described in paragraphs [0081]-[0109] of US 2018/0221396 Al and [0082]-[0110] US 2019/0142851 Al as well as the disclosed exemplary embodiments.
  • Exemplary cannabinoids include but are not limited to the cannabinoids described in paragraphs [01 ll]-[0145] of US 2018/0221396 Al and [0112]-[0146] US 2019/0142851 Al as well as the disclosed exemplary embodiments.
  • Exemplary terpenes include but are not limited to the terpenes described in paragraphs [0160]-[0238] of US 2018/0221396 Al and [0161]-[0300] US 2019/0142851 Al as well as the disclosed exemplary embodiments.
  • a pharmaceutical formulation of the disclosure may comprise, consist essentially of, or consist of (a) 4-(methylsulfonyloxy)-DPT chloride, crystalline 4-(methylsulfonyloxy)-DPT chloride, 4-(4-trifluoromethylbenzoyloxy)-DPT chloride, crystalline 4-(4-trifluoromethylbenzoyloxy)-DPT chloride, 4-(4-fluorobenzoyloxy)-DPT chloride, crystalline 4-(4-fluorobenzoyloxy)-DPT chloride, 4- PivO-DPT chloride, crystalline 4-PivO-DPT chloride, 4-Pro-DMT hydrofumarate, crystalline 4-Pro-DMT hydrofumarate, 4-[(4-nitrophenyl)sulfonyloxy]-DPT chloride hydrate, crystalline 4-[(4- nitrophenyl)sulfonyloxy]-DPT chloride hydrate, or specific crystalline forms thereof, such as crystalline
  • a pharmaceutical formulation of the disclosure may comprise a composition containing 4-(methylsulfonyloxy)-DPT chloride, crystalline 4-(methylsulfonyloxy)-DPT chloride, 4-(4- trifluoromethylbenzoyloxy)-DPT chloride, crystalline 4-(4-trifluoromethylbenzoyloxy)-DPT chloride, 4-(4-fluorobenzoyloxy)-DPT chloride, crystalline 4-(4-fluorobenzoyloxy)-DPT chloride, 4-PivO-DPT chloride, crystalline 4-PivO-DPT chloride, 4-Pro-DMT hydrofumarate, crystalline 4-Pro-DMT hydrofumarate, 4-[(4-nitrophenyl)sulfonyloxy]-DPT chloride hydrate, crystalline 4-[(4- nitrophenyl)sulfonyloxy]-DPT chloride hydrate, or specific crystalline forms thereof, such as crystalline form 1 of 4-(methyl)-methyl
  • compositions comprising a combination of a purified psilocybin derivative with a second purified psilocybin derivative, with one or two purified cannabinoids or with a purified terpene.
  • the disclosure provides a pharmaceutical formulation comprising as (a) 4-(methylsulfonyloxy)-DPT chloride, crystalline 4-(methylsulfonyloxy)-DPT chloride, 4-(4-trifluoromethylbenzoyloxy)-DPT chloride, crystalline 4-(4-trifluoromethylbenzoyloxy)-DPT chloride, 4-(4-fluorobenzoyloxy)-DPT chloride, crystalline 4-(4-fluorobenzoyloxy)-DPT chloride, 4- PivO-DPT chloride, crystalline 4-PivO-DPT chloride, 4-Pro-DMT hydrofumarate, crystalline 4-Pro-DMT hydrofumarate, 4-[(4-nitrophenyl)sulfonyloxy]-DPT chloride hydrate, crystalline 4-[
  • a serotonergic drug refers to a compound that binds to, blocks, or otherwise influences (e.g., via an allosteric reaction) activity at a serotonin receptor as described in paragraphs [0245]-[0253] of US 2018/0221396 Al and [0305]-[0311] US 2019/0142851 Al as well as the disclosed exemplary embodiments.
  • Some exemplary serotonergic drugs include SSRIs and SNRIs.
  • serotonergic drugs include the following molecules, including any salts, solvates, or polymorphs thereof: 6-a Ilyl-N, N-diethyl-N L; N,N-dibutyl-T; N,N-diethyl-T; N,N- diisopropyl-T; 5-methyoxy-alpha-methyl-T; N,N-dimethyl-T; 2,alpha-dimethyl-T; alpha, N-dimethyl-T; N,N-dipropyl-T; N-ethyl-N-isopropyl-T; alpha-ethyl-T; 6-N,N-Triethyl-NL; 3,4-dihydro-7-methoxy-l- methyl-C; 7-methyoxy-l-methyl-C; N,N-dibutyl-4-hydroxy-T; N,N-diethyl-4-hydroxy-T; N,N- diisopropyl-4-hydroxy-
  • a serotonergic drug is chosen from alprazolam, amphetamine, aripiprazole, azapirone, a barbiturate, bromazepam, bupropion, buspirone, a cannabinoid, chlordiazepoxide, citalopram, clonazepam, clorazepate, dextromethorphan, diazepam, duloxetine, escitalopram, fluoxetine, flurazepam, fluvoxamine, lorazepam, lysergic acid diethylamide, lysergamide, 3,4- methylenedioxymethamphetamine, milnacipran, mirtazapine, naratriptan, paroxetine, pethidine, phene
  • Exemplary psilocybin derivatives include but are not limited to psilocybin itself and the psilocybin derivatives described in paragraphs [0081]-[0109] of US 2018/0221396 Al and [0082]- [0110] US 2019/0142851 Al as well as the disclosed exemplary embodiments, incorporated here by reference.
  • compositions disclosed herein comprise one or more purified psilocybin derivatives chosen from: [3-(2-dimethylaminoethyl)-lH-indol-4-yl] dihydrogen phosphate; 4-hydroxytryptamine; 4-hydroxy-N,N-dimethyltryptamine; [3-(2-methylaminoethyl)-lH-indol-4-yl] dihydrogen phosphate; 4-hydroxy-N-methyltryptamine; [3-(aminoethyl)-lH-indol-4-yl] dihydrogen phosphate; [3-(2-trimethylaminoethyl)-lH-indol-4-yl] dihydrogen phosphate; and 4-hydroxy-N,N,N- trimethyltryptamine.
  • purified psilocybin derivatives chosen from: [3-(2-dimethylaminoethyl)-lH-indol-4-yl
  • Exemplary cannabinoids include but are not limited to the cannabinoids described in paragraphs [01 ll]-[0145] of US 2018/0221396 Al and [0112]-[0146] US 2019/0142851 Al as well as the disclosed exemplary embodiments.
  • cannabinoids within the context of this disclosure include the following molecules: cannabichromene (CBC); cannabichromenic acid (CBCA); cannabichromevarin (CBCV); cannabichromevarinic acid (CBCVA); cannabicyclol (CBL); cannabicyclolic acid (CBLA); cannabicyclovarin (CBLV); cannabidiol (CBD); cannabidiol monomethylether (CBDM); cannabidiolic acid (CBDA); cannabidiorcol (CBD-C1); cannabidivarin (CBDV); cannabidivarinic acid (CBDVA); cannabielsoic acid B (CBEA-B); cannabielsoin (CBE); cannabielsoin acid A (CBEA-A); cannabigerol (CBG); cannabigerol monomethylether (CBGM); cannabigerolic acid (CBGA); cannabigerolic acid
  • the purified cannabinoid is chosen from THC, THCA, THCV, THCVA, CBC, CBCA, CBCV, CBCVA, CBD, CBDA, CBDV, CBVD, CBDVA, CBG, CBGA, CBGV, or CBGVA.
  • Exemplary terpenes include but are not limited to the terpenes described in paragraphs [0160]-[0238] of US 2018/0221396 Al and [0161]-[0300] US 2019/0142851 Al as well as the disclosed exemplary embodiments.
  • a purified terpene is chosen from acetanisole, acetyl cedrene, anethole, anisole, benzaldehyde, bornyl acetate, borneol, cadinene, cafestol, caffeic acid, camphene, camphor, capsaicin, carene, carotene, carvacrol, carvone, caryophyllene, caryophyllene, caryophyllene oxide, cedrene, cedrene epoxide, cecanal, cedrol, cembrene, cinnamaldehyde, cinnamic acid, citronellal, citronellol, cymene, eicosane, elemene, estragole, ethyl acetate, ethyl cinnamate, ethyl maltol, eucalyptol/l,8-cineole, eudes
  • a purified terpene is chosen from bornyl acetate, alpha- bisabolol, borneol, camphene, camphor, carene, caryophyllene, cedrene, cymene, elemene, eucalyptol, eudesmol, farnesene, fenchol, geraniol, guaiacol, humulene, isoborneol, limonene, linalool, menthol, myrcene, nerolidol, ocimene, phellandrene, phytol, pinene, pulegone, sabinene, terpineol, terpinolene, or valencene.
  • adrenergic drug refers to a compound that binds, blocks, or otherwise influences (e.g., via an allosteric reaction) activity at an adrenergic receptor.
  • an adrenergic drug binds to an adrenergic receptor.
  • an adrenergic drug indirectly affects an adrenergic receptor, e.g., via interactions affecting the reactivity of other molecules at the adrenergic receptor.
  • an adrenergic drug is an agonist, e.g., a compound activating an adrenergic receptor.
  • an adrenergic drug is an antagonist, e.g., a compound binding but not activating an adrenergic receptor, e.g., blocking a receptor.
  • an adrenergic drug is an effector molecule, e.g., a compound binding to an enzyme for allosteric regulation.
  • an adrenergic drug acts (either directly or indirectly) at more than one type of receptor (e.g., 5HT, dopamine, adrenergic, acetylcholine, etc.).
  • an adrenergic drug is an antidepressant. In one embodiment, an adrenergic drug is a norepinephrine transporter inhibitor. In one embodiment, an adrenergic drug is a vesicular monoamine transporter inhibitor.
  • an adrenergic drug is chosen from adrenaline, agmatine, amoxapine, aptazapine, atomoxetine, bupropion, clonidine, doxepin, duloxetine, esmirtazpine, mianserin, ketanserin, mirabegron, mirtazapine, norepinephrine, phentolamine, phenylephrine, piperoxan, reserpine, ritodrine, setiptiline, tesofensine, timolol, trazodone, trimipramine, or xylazine.
  • the term "dopaminergic drug” refers to a compound that binds, blocks, or otherwise influences (e.g., via an allosteric reaction) activity at a dopamine receptor.
  • a dopaminergic drug binds to a dopamine receptor.
  • a dopaminergic drug indirectly affects a dopamine receptor, e.g., via interactions affecting the reactivity of other molecules at the dopamine receptor.
  • a dopaminergic drug is an agonist, e.g., a compound activating a dopamine receptor.
  • a dopaminergic drug is an antagonist, e.g., a compound binding but not activating a dopamine receptor, e.g., blocking a receptor.
  • a dopaminergic drug is an effector molecule, e.g., a compound binding to an enzyme for allosteric regulation.
  • a dopaminergic drug acts (either directly or indirectly) at more than one type of receptor (e.g., 5HT, dopamine, adrenergic, acetylcholine, etc.).
  • a dopaminergic drug is a dopamine transporter inhibitor.
  • a dopaminergic drug is a vesicular monoamine transporter inhibitor.
  • a dopaminergic drug is chosen from amineptine, apomorphine, benzylpiperazine, bromocriptine, cabergoline, chlorpromazine, clozapine, dihydrexidine, domperidone, dopamine, fluphenazine, haloperidol, ketamine, loxapine, methamphetamine, olanzapine, pemoline, perphenazine, pergolide, phencyclidine, phenethylamine, phenmetrazine, pimozide, piribedil, a psychostimulant, reserpine, risperidone, ropinirole, tetrabenazine, or thioridazine.
  • a MAOI refers to a compound that blocks the actions of monoamine oxidase enzymes.
  • a MAOI inhibits the activity of one or both monoamine oxidase A and monoamine oxidase B.
  • a MAOI is a reversible inhibitor of monoamine oxidase A.
  • a MAOI is a drug chosen from isocarboxazid, phenelzine, or tranylcypromine.
  • a MAOI is 0- carboline, pinoline, harmane, harmine, harmaline, harmalol, tetrahydroharmine, 9-methyl-0- carboline, or 3-carboxy-tetrahydrononharman.
  • the compositions and methods disclosed herein include one or more purified erinacine molecules.
  • the compositions and methods disclosed herein comprise purified erinacine A.
  • the compositions and methods disclosed herein comprise erinacine B.
  • the compositions and methods disclosed herein comprise erinacine C.
  • the compositions and methods disclosed herein comprise erinacine D.
  • the compositions and methods disclosed herein comprise erinacine E.
  • the compositions and methods disclosed herein comprise erinacine F.
  • the compositions and methods disclosed herein comprise erinacine G.
  • the compositions and methods disclosed herein comprise erinacine H.
  • compositions and methods disclosed herein comprise erinacine I. In one embodiment, the compositions and methods disclosed herein comprise erinacine J. In one embodiment, the compositions and methods disclosed herein comprise erinacine K In one embodiment, the compositions and methods disclosed herein comprise erinacine P. In one embodiment, the compositions and methods disclosed herein comprise erinacine Q.. In one embodiment, the compositions and methods disclosed herein comprise erinacine R. In one embodiment, the compositions and methods disclosed herein comprise erinacine S.
  • compositions and methods disclosed herein include one or more purified hericenone molecules.
  • the compositions and methods disclosed herein comprise purified hericenone A.
  • the compositions and methods disclosed herein comprise purified hericenone B.
  • the compositions and methods disclosed herein comprise purified hericenone C.
  • the compositions and methods disclosed herein comprise purified hericenone D.
  • the compositions and methods disclosed herein comprise purified hericenone E.
  • the compositions and methods disclosed herein comprise purified hericenone F.
  • the compositions and methods disclosed herein comprise purified hericenone G.
  • the compositions and methods disclosed herein comprise purified hericenone H.
  • the actual amount required for treatment of any particular patient may depend upon a variety of factors including, for example, the disease being treated and its severity; the specific pharmaceutical composition employed; the age, body weight, general health, sex, and diet of the patient; the mode of administration; the time of administration; the route of administration; and the rate of excretion; the duration of the treatment; any drugs used in combination or coincidental with the specific compound employed; and other such factors well known in the medical arts. These factors are discussed in Goodman and Gilman's "The Pharmacological Basis of Therapeutics," Tenth Edition, A. Gilman, J. Hardman and L. Limbird, eds., McGraw-Hill Press, 155-173 (2001), which is incorporated herein by reference.
  • the pharmaceutically acceptable carrier may be chosen from any one or a combination of carriers known in the art.
  • the choice of the pharmaceutically acceptable carrier depends upon the pharmaceutical form and the desired method of administration to be used.
  • Exemplary carriers include those that do not substantially alter the structure or activity of 4-(methylsulfonyloxy)-DPT chloride, crystalline 4- (methylsulfonyloxy)-DPT chloride, 4-(4-trifluoromethylbenzoyloxy)-DPT chloride, crystalline 4-(4- trifluoromethylbenzoyloxy)-DPT chloride, 4-(4-fluorobenzoyloxy)-DPT chloride, crystalline 4-(4- fluorobenzoyloxy)-DPT chloride, 4-PivO-DPT chloride, crystalline 4-PivO-DPT chloride, 4-Pro-DMT hydrofumarate, crystalline 4-Pro-DMT hydrofumarate, 4-[(4-nitrophenyl)sulfonyl
  • compositions of the disclosure may be prepared by methods know in the pharmaceutical formulation art, for example, see Remington's Pharmaceutical Sciences, 18th Ed., (Mack Publishing Company, Easton, Pa., 1990), which is incorporated herein by reference.
  • a solid dosage form 4-(methylsulfonyloxy)-DPT chloride, crystalline 4-(methylsulfonyloxy)-DPT chloride, 4-(4-trifluoromethylbenzoyloxy)-DPT chloride, crystalline 4-(4-trifluoromethylbenzoyloxy)- DPT chloride, 4-(4-fluorobenzoyloxy)-DPT chloride, crystalline 4-(4-fluorobenzoyloxy)-DPT chloride, 4-PivO-DPT chloride, crystalline 4-PivO-DPT chloride, 4-Pro-DMT hydrofumarate, crystalline 4-Pro- DMT hydrofumarate, 4-[(4-nitrophenyl)sulfonyloxy]-D
  • the dosage forms may also comprise buffering agents.
  • the excipient is not water.
  • the excipient is not a solvent (e.g., EtOH, diethyl ether, ethyl acetate, or hydrocarbon-based solvents (e.g., hexanes).
  • the dosage form is substantially free of water and/or solvents, for example less than about 5% water by mass, less than 2% water by mass, less than 1% water by mass, less than 0.5% water by mass, or less than 0.1% water by mass.
  • Excipients or pharmaceutically acceptable adjuvants known in the pharmaceutical formulation art may also be used in the pharmaceutical compositions of the disclosure. These include, but are not limited to, preserving, wetting, suspending, sweetening, flavoring, perfuming, emulsifying, and dispensing agents. Prevention of the action of microorganisms may be ensured by inclusion of various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example, sugars, sodium chloride, and the like.
  • a pharmaceutical composition of the disclosure may also contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, antioxidants, and the like, such as, for example, citric acid, sorbitan monolaurate, triethanolamine oleate, butylated hydroxytoluene, etc.
  • auxiliary substances such as wetting or emulsifying agents, pH buffering agents, antioxidants, and the like, such as, for example, citric acid, sorbitan monolaurate, triethanolamine oleate, butylated hydroxytoluene, etc.
  • Solid dosage forms as described above may be prepared with coatings and shells, such as enteric coatings and others well known in the art. They may contain pacifying agents and can also be of such composition that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner.
  • Non-limiting examples of embedded compositions that may be used are polymeric substances and waxes.
  • the active compounds may also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.
  • Suspensions in addition to the active compounds, may contain suspending agents, such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.
  • suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.
  • Solid dosage forms for oral administration which includes capsules, tablets, pills, powders, and granules, may be used. In such solid dosage forms, the active compound may be mixed with at least one inert, pharmaceutically acceptable excipient (also known as a pharmaceutically acceptable carrier).
  • administration may be, for example, orally, buccally, nasally, parenterally (intravenous, intramuscular, or subcutaneous), topically, transdermally, intravagi na lly, intravesically, or intrasystemically, in the form of solid, semisolid, lyophilized powder, or liquid dosage forms, such as, for example, tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, or aerosols, or the like, such as, for example, in unit dosage forms suitable for simple administration of precise dosages.
  • One route of administration may be oral administration, using a convenient daily dosage regimen that can be adjusted according to the degree of severity of the disease-state to be treated.
  • E4 A composition comprising crystalline 4-pivaloyloxy-A/,A/-di-n- propyltryptammonium chloride according to any one of E1-E3 and an excipient.
  • E5. A composition comprising crystalline 4-pivaloyloxy-A/,/ ⁇ /-di-n- propyltryptammonium chloride according to any one of E1-E3 as a first component and a second component selected from at least one of (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) a purified cannabinoid, (d) a purified terpene, (e) an adrenergic drug, (f) a dopaminergic drug, (g) a monoamine oxidase inhibitor, (h) a purified erinacine, and (i) a purified hericenone.
  • E6 A method of preventing or treating a psychological disorder comprising the step of: administering to a subject in need thereof a therapeutically effective amount of crystalline 4- pivaloyloxy-A/,A/-di-n-propyltryptammonium chloride according to any one of E1-E3.
  • a method of preventing or treating a psychological disorder comprising the step of: administering to a subject in need thereof a composition according to E4 or E5.
  • E8 A method of preventing or treating inflammation and/or pain comprising the step of: administering to a subject in need thereof a therapeutically effective amount of crystalline 4- pivaloyloxy-A/,A/-di-n-propyltryptammonium chloride according to any one of E1-E3.
  • a method of preventing or treating inflammation and/or pain comprising the step of: administering to a subject in need thereof a composition according to E4 or E5.
  • E13 A composition comprising crystalline 4-(methylsulfonyloxy)-A/,A/-di-n- propyltryptammonium chloride according to any one of E10-E12 and an excipient.
  • E14 A composition comprising crystalline 4-(methylsulfonyloxy)-/V,/V-di-n- propyltryptammonium chloride according to any one of E10-E12 as a first component and a second component selected from at least one of (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) a purified cannabinoid, (d) a purified terpene, (e) an adrenergic drug, (f) a dopaminergic drug, (g) a monoamine oxidase inhibitor, (h) a purified erinacine, and (i) a purified hericenone.
  • E15 A method of preventing or treating a psychological disorder comprising the step of: administering to a subject in need thereof a therapeutically effective amount of crystalline 4- (methylsulfonyloxy)-A/,A/-di-n-propyltryptammonium chloride according to any one of E10-E12.
  • E16 A method of preventing or treating a psychological disorder comprising the step of: administering to a subject in need thereof a composition according to E13 or E14.
  • E17 A method of preventing or treating inflammation and/or pain comprising the step of: administering to a subject in need thereof a therapeutically effective amount of crystalline 4- (methylsulfonyloxy)-A/,A/-di-n-propyltryptammonium chloride according to any one of E10-E12.
  • E18 A method of preventing or treating inflammation and/or pain comprising the step of: administering to a subject in need thereof a composition according to E13 or E14.
  • E20 Crystalline dipropyl(2- ⁇ 4-[4-(trifluoromethyl)benzoyloxy]-lH-indol-3- yl ⁇ ethyl)azanium chloride (4-(4-trifluoromethylbenzoyloxy)-A/,/V-di-n-propyltryptammonium chloride).
  • E21 Crystalline form 1 of dipropyl(2- ⁇ 4-[4-(trifluoromethyl)benzoyloxy]-lH-indol-3- yl ⁇ ethyl)azanium chloride (4-(4-trifluoromethylbenzoyloxy)-A/,A/-di-n-propyltryptammonium chloride).
  • E23 A composition comprising 4-(4-trifluoromethylbenzoyloxy)-A/,A/-di-n- propyltryptammonium chloride according to E19 and an excipient.
  • E24 A composition comprising crystalline 4-(4-trifluoromethylbenzoyloxy)-A/,A/-di-n- propyltryptammonium chloride according to any one of E20-E22 and an excipient.
  • a composition comprising 4-(4-trifluoromethylbenzoyloxy)-A/,/V-di-n- propyltryptammonium chloride according to E19 as a first component and a second component selected from at least one of (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) a purified cannabinoid, (d) a purified terpene, (e) an adrenergic drug, (f) a dopaminergic drug, (g) a monoamine oxidase inhibitor, (h) a purified erinacine, and (i) a purified hericenone.
  • E26 A composition comprising crystalline 4-(4-trifluoromethylbenzoyloxy)-A/,A/-di-n- propyltryptammonium chloride according to any one of E20-E22 as a first component and a second component selected from at least one of (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) a purified cannabinoid, (d) a purified terpene, (e) an adrenergic drug, (f) a dopaminergic drug, (g) a monoamine oxidase inhibitor, (h) a purified erinacine, and (i) a purified hericenone.
  • E27 A method of preventing or treating a psychological disorder comprising the step of: administering to a subject in need thereof a therapeutically effective amount of 4-(4- trifluoromethylbenzoyloxy)-A/,A/-di-n-propyltryptammonium chloride according to E19.
  • E28 A method of preventing or treating a psychological disorder comprising the step of: administering to a subject in need thereof a therapeutically effective amount of crystalline 4- (4-trifluoromethylbenzoyloxy)-A/,A/-di-n-propyltryptammonium chloride according to any one of E20- E22.
  • E29 A method of preventing or treating a psychological disorder comprising the step of: administering to a subject in need thereof a composition according to E23 or E25.
  • E30 A method of preventing or treating a psychological disorder comprising the step of: administering to a subject in need thereof a composition according to E24 or E26.
  • E31 A method of preventing or treating inflammation and/or pain comprising the step of: administering to a subject in need thereof a therapeutically effective amount of 4-(4- trifluoromethylbenzoyloxy)-A/,A/-di-n-propyltryptammonium chloride according to E19.
  • E32 A method of preventing or treating inflammation and/or pain comprising the step of: administering to a subject in need thereof a therapeutically effective amount of crystalline 4- (4-trifluoromethylbenzoyloxy)-A/,A/-di-n-propyltryptammonium chloride according to any one of E20- E22.
  • E33 A method of preventing or treating inflammation and/or pain comprising the step of: administering to a subject in need thereof a composition according to E23 or E25.
  • E34 A method of preventing or treating inflammation and/or pain comprising the step of: administering to a subject in need thereof a composition according to E24 or E26.
  • E36 Crystalline form 1 of ⁇ 2-[4-(4-fluorobenzoyloxy)-lH-indol-3- yl]ethyl ⁇ dipropylazanium chloride (4-(4-fluorobenzoyloxy)-A/,A/-di-n-propyltryptammonium chloride). [00142] E37.
  • E38 A composition comprising crystalline 4-(4-fluorobenzoyloxy)-A/,A/-di-n- propyltryptammonium chloride according to any one of E35-E37 and an excipient. [00144] E39.
  • a composition comprising crystalline 4-(4-fluorobenzoyloxy)-/V,/V-di-n- propyltryptammonium chloride according to any one of E35-E37 as a first component and a second component selected from at least one of (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) a purified cannabinoid, (d) a purified terpene, (e) an adrenergic drug, (f) a dopaminergic drug, (g) a monoamine oxidase inhibitor, (h) a purified erinacine, and (i) a purified hericenone.
  • E40 A method of preventing or treating a psychological disorder comprising the step of: administering to a subject in need thereof a therapeutically effective amount of crystalline 4- (4-fluorobenzoyloxy)-/V,A/-di-n-propyltryptammonium chloride according to any one of E35-E37.
  • E41 A method of preventing or treating a psychological disorder comprising the step of: administering to a subject in need thereof a composition according to E38 or E39.
  • E42 A method of preventing or treating inflammation and/or pain comprising the step of: administering to a subject in need thereof a therapeutically effective amount of crystalline 4- (4-fluorobenzoyloxy)-A/,A/-di-n-propyltryptammonium chloride according to any one of E35-E37.
  • E43 A method of preventing or treating inflammation and/or pain comprising the step of: administering to a subject in need thereof a composition according to E38 or E39.
  • E45 Crystalline form 1 of dimethyl( ⁇ 2-[4-(propanoyloxy)-lH-indol-3- yl]ethyl ⁇ )azanium (2E)-3-carboxyprop-2-enoate (4-propanoyloxy-A/,A/-dimethyltryptammonium hydrofumarate).
  • E47 A composition comprising crystalline 4-propanoyloxy-A/,/V- dimethyltryptammonium hydrofumarate according to any one of E44-E46 and an excipient.
  • E48 A composition comprising crystalline 4-propanoyloxy-A/,/V- dimethyltryptammonium hydrofumarate according to any one of E44-E46 as a first component and a second component selected from at least one of (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) a purified cannabinoid, (d) a purified terpene, (e) an adrenergic drug, (f) a dopaminergic drug, (g) a monoamine oxidase inhibitor, (h) a purified erinacine, and (i) a purified hericenone.
  • E49 A method of preventing or treating a psychological disorder comprising the step of: administering to a subject in need thereof a therapeutically effective amount of crystalline 4- propanoyloxy-/V,/V-dimethyltryptammonium hydrofumarate according to any one of E44-E46.
  • E50 A method of preventing or treating a psychological disorder comprising the step of: administering to a subject in need thereof a composition according to E47 or E48.
  • E51 A method of preventing or treating inflammation and/or pain comprising the step of: administering to a subject in need thereof a therapeutically effective amount of crystalline 4- propanoyloxy-/V,/V-dimethyltryptammonium hydrofumarate according to any one of E44-E46.
  • E52 A method of preventing or treating inflammation and/or pain comprising the step of: administering to a subject in need thereof a composition according to E47 or E48.
  • E53 (2- ⁇ 4-[(4-nitrobenzenesulfonyl)oxy]-lH-indol-3-yl ⁇ ethyl)dipropylazanium chloride hydrate (4-[(4-nitrophenyl)sulfonyloxy]-N,N-di-n-propyltryptammonium chloride hydrate). [00159] E54.
  • E58 A composition comprising crystalline 4-[(4-nitrophenyl)sulfonyloxy]-A/,A/-di-n- propyltryptammonium chloride hydrate according to any one of E54-E56 and an excipient.
  • a composition comprising 4-[(4-nitrophenyl)sulfonyloxy]-N,N-di-n- propyltryptammonium chloride hydrate according to E53 as a first component and a second component selected from at least one of (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) a purified cannabinoid, (d) a purified terpene, (e) an adrenergic drug, (f) a dopaminergic drug, (g) a monoamine oxidase inhibitor, (h) a purified erinacine, and (i) a purified hericenone.
  • E60 A composition comprising crystalline 4-[(4-nitrophenyl)sulfonyloxy]-M,A/-di-n- propyltryptammonium chloride hydrate according to any one of E54-E56 as a first component and a second component selected from at least one of (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) a purified cannabinoid, (d) a purified terpene, (e) an adrenergic drug, (f) a dopaminergic drug, (g) a monoamine oxidase inhibitor, (h) a purified erinacine, and (i) a purified hericenone.
  • E61 A method of preventing or treating a psychological disorder comprising the step of: administering to a subject in need thereof a therapeutically effective amount of 4-[(4- nitrophenyl)sulfonyloxy]-N,N-di-n-propyltryptammonium chloride hydrate according to E53.
  • E62 A method of preventing or treating a psychological disorder comprising the step of: administering to a subject in need thereof a therapeutically effective amount of crystalline 4- [(4-nitrophenyl)sulfonyloxy]-A/,A/-di-n-propyltryptammonium chloride hydrate according to any one of E54-E56.
  • E63 A method of preventing or treating a psychological disorder comprising the step of: administering to a subject in need thereof a composition according to E57 or E59.
  • E64 A method of preventing or treating a psychological disorder comprising the step of: administering to a subject in need thereof a composition according to E58 or E60.
  • E65 A method of preventing or treating inflammation and/or pain comprising the step of: administering to a subject in need thereof a therapeutically effective amount of 4-[(4- nitrophenyl)sulfonyloxy]-N,N-di-n-propyltryptammonium chloride hydrate according to E53.
  • E66 A method of preventing or treating inflammation and/or pain comprising the step of: administering to a subject in need thereof a therapeutically effective amount of crystalline 4- [(4-nitrophenyl)sulfonyloxy]-A/,/V-di-n-propyltryptammonium chloride hydrate according to any one of E54-E56.
  • E67 A method of preventing or treating inflammation and/or pain comprising the step of: administering to a subject in need thereof a composition according to E57 or E59.
  • E68 A method of preventing or treating inflammation and/or pain comprising the step of: administering to a subject in need thereof a composition according to E58 or E60.
  • Triethylamine (2 equiv.) was added to a reaction vial containing 3-(2- (dipropylamino)ethyl)-lH-indol-4-ol (0.4 mmol, 1 equiv.) in anhydrous DCM (8 mL) at 0 °C followed by methanesulfonyl chloride (1.5 equiv.) in a dropwise manner.
  • the resulting contents were then stirred at room temperature under nitrogen until the disappearance of the starting material (per TLC). The typical reaction times were between 1.5 to 2h.
  • the reaction contents were then diluted with DCM (20 mL) and washed twice with cold water followed by brine.
  • Triethylamine (2 equiv.) was added to a reaction vial containing 3-(2- (dipropylamino)ethyl)-lH-indol-4-ol (0.4 mmol, 1 equiv.) in anhydrous DCM (8 mL) at 0 °C followed by 4-(trifluoromethyl)benzoyl chloride (1.5 equiv.) in a dropwise manner.
  • the resulting contents were then stirred at room temperature under nitrogen until the disappearance of the starting material (per TLC). The typical reaction times were between 1.5 to 2h.
  • the reaction contents were then diluted with DCM (20 mL) and washed twice with cold water followed by brine.
  • Triethylamine (2 equiv.) was added to a reaction vial containing 3-(2- (dipropylamino)ethyl)-lH-indol-4-ol (0.4 mmol, 1 equiv.) in anhydrous DCM (8 mL) at 0 °C followed by 4-fluorobenzoyl chloride (1.5 equiv.) in a dropwise manner.
  • the resulting contents were then stirred at room temperature under nitrogen until the disappearance of the starting material (per TLC). The typical reaction times were between 1.5 to 2h.
  • the reaction contents were then diluted with DCM (20 mL) and washed twice with cold water followed by brine.
  • Triethylamine (2 equiv.) was added to a reaction vial containing 3-(2- (dipropylamino)ethyl)-lH-indol-4-ol (0.4 mmol, 1 equiv.) in anhydrous DCM (8 mL) at 0 °C followed by pivaloyl chloride (1.5 equiv.) in a dropwise manner.
  • the resulting contents were then stirred at room temperature under nitrogen until the disappearance of the starting material (perTLC). The typical reaction times were between 1.5 to 2h.
  • the reaction contents were then diluted with DCM (20 mL) and washed twice with cold water followed by brine.
  • Triethylamine (2 equiv.) was added to a reaction vial containing 3-(2- (dipropylamino)ethyl)-lH-indol-4-ol (0.4 mmol, 1 equiv.) in anhydrous DCM (8 mL) at 0 °C followed by 4-nitrobenzenesulfonyl chloride (1.5 equiv.) in a dropwise manner.
  • the resulting contents were then stirred at room temperature under nitrogen until the disappearance of the starting material (per TLC). The typical reaction times were between 1.5 to 2h.
  • the reaction contents were then diluted with DCM (20 mL) and washed twice with cold water followed by brine.
  • FIG. 1 shows the molecular structure of crystalline form 1 of 4-(methylsulfonyloxy)- DPT chloride, showing the atomic labeling.
  • FIG. 2 shows the molecular structure of crystalline form 1 of 4-(4- trifluoromethylbenzoyloxy)-DPT chloride, showing the atomic labeling.
  • FIG. 3 shows the molecular structure of crystalline form 1 of 4-(4-fluorobenzoyloxy)- DPT chloride, showing the atomic labeling.
  • FIG. 4 shows the molecular structure of crystalline form 1 of 4-PivO-DPT chloride, showing the atomic labeling.
  • FIG. 5 shows the molecular structure of crystalline form 1 of 4-Pro-DMT hydrofumarate, showing the atomic labeling.
  • FIG. 6 shows the molecular structure of crystalline form 1 of 4-[(4- nitrophenyl)sulfonyloxy]-DPT chloride hydrate, showing the atomic labeling.
  • FIG. 7 shows the unit cell of crystalline form 1 of 4-(methylsulfonyloxy)-DPT chloride along the a-axis.
  • FIG. 8 shows the unit cell of crystalline form 1 of 4-(4-trifluoromethylbenzoyloxy)- DPT chloride along the b-axis.
  • FIG. 9 shows the unit cell of crystalline form 1 of 4-(4-fluorobenzoyloxy)-DPT chloride along the b-axis.
  • FIG. 10 shows the unit cell of crystalline form 1 of 4-PivO-DPT chloride along the a- axis.
  • FIG. 11 shows the unit cell of crystalline form 1 of 4-Pro-DMT hydrofumarate along the b-axis.
  • FIG. 12 shows the unit cell of crystalline form 1 of 4-[(4-nitrophenyl)sulfonyloxy]-DPT chloride hydrate along the a-axis.
  • FIG. 13 shows a simulated X-ray powder diffraction pattern (XRPD) for crystalline form 1 of 4-(methylsulfonyloxy)-DPT chloride generated from its single crystal data.
  • Table 4 lists the angles, °20 ⁇ O.2°20, and d-spacing of the peaks identified in the experimental XRPD pattern of FIG. 13. The entire list of peaks, or a subset thereof, may be sufficient to characterize the cocrystal.
  • the cocrystal may be characterized by at least two peaks selected from the peaks at 7.6,
  • FIG. 14 shows a simulated X-ray powder diffraction pattern (XRPD) for crystalline form 1 of 4-(4-trifluoromethylbenzoyloxy)-DPT chloride generated from its single crystal data.
  • Table 5 lists the angles, °20 ⁇ O.2°20, and d-spacing of the peaks identified in the experimental XRPD pattern of FIG. 14. The entire list of peaks, or a subset thereof, may be sufficient to characterize the cocrystal.
  • the cocrystal may be characterized by at least two peaks selected from the peaks at 7.6, 9.8, and 10.8 °20 ⁇ O.2°20 or their corresponding d-spacing as well as by an XRPD pattern substantially similar to FIG. 14.
  • FIG. 15 shows a simulated X-ray powder diffraction pattern (XRPD) for crystalline form 1 of 4-(4-fluorobenzoyloxy)-DPT chloride generated from its single crystal data.
  • Table 6 lists the angles, °20 ⁇ O.2°20, and d-spacing of the peaks identified in the experimental XRPD pattern of FIG. 15. The entire list of peaks, or a subset thereof, may be sufficient to characterize the cocrystal.
  • the cocrystal may be characterized by at least two peaks selected from the peaks at 7.4,
  • FIG. 16 shows a simulated X-ray powder diffraction pattern (XRPD) for crystalline form 1 of 4-PivO-DPT chloride generated from its single crystal data.
  • Table 7 lists the angles, °20 ⁇ O.2°20, and d-spacing of the peaks identified in the experimental XRPD pattern of FIG. 16. The entire list of peaks, or a subset thereof, may be sufficient to characterize the cocrystal.
  • the cocrystal may be characterized by at least two peaks selected from the peaks at 6.8, 8.1, and 10.1 °20 ⁇ O.2°20 or their corresponding d-spacing as well as by an XRPD pattern substantially similar to FIG. 16.
  • FIG. 17 shows a simulated X-ray powder diffraction pattern (XRPD) for crystalline form 1 of 4-Pro-DMT hydrofumarate generated from its single crystal data.
  • Table 8 lists the angles, °20 ⁇ 0.2°26, and d-spacing of the peaks identified in the experimental XRPD pattern of FIG. 17. The entire list of peaks, or a subset thereof, may be sufficient to characterize the cocrystal.
  • the cocrystal may be characterized by at least two peaks selected from the peaks at 9.8, 15.8, and 18.6 °20 ⁇ O.2°20 or their corresponding d-spacing as well as by an XRPD pattern substantially similar to FIG. 17.
  • FIG. 18 shows a simulated X-ray powder diffraction pattern (XRPD) for crystalline form 1 of 4-[(4-nitrophenyl)sulfonyloxy]-DPT chloride hydrate generated from its single crystal data.
  • Table 9 lists the angles, °20 ⁇ O.2°20, and d-spacing of the peaks identified in the experimental XRPD pattern of FIG. 18. The entire list of peaks, or a subset thereof, may be sufficient to characterize the cocrystal.
  • the cocrystal may be characterized by at least two peaks selected from the peaks at 14.3, 17.1, and 20.6 °20 ⁇ 0.2°20 or their corresponding d-spacing as well as by an XRPD pattern substantially similar to FIG. 18.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente divulgation concerne du chlorure de {2-[4-(méthanesulfonyloxy)-1H-indol-3-yl]éthyl}dipropylazanium (chlorure de 4-(méthylsulfonyloxy)-N,N-di-n-propyltryptammonium ou chlorure de 4-(méthylsulfonyloxy)-DPT), du chlorure de 4-(méthylsulfonyloxy)-DPT cristallin, du chlorure de dipropyl(2-{4-[4-(trifluorométhyl)benzoyloxy]-1H-indol-3-yl}éthyl)azanium (chlorure de 4-(4-trifluorométhylbenzoyloxy)-N,N-di-n-propyltryptammonium ou chlorure de 4-(4-trifluorométhylbenzoyloxy)-DPT), du chlorure de 4-(4-trifluorométhylbenzoyloxy)-DPT cristallin, du chlorure de {2-[4-(4-fluorobenzoyloxy)-1H-indol-3-yl]éthyl}dipropylazanium (chlorure de 4-(4-fluorobenzoyloxy)-N,N-di-n-propyltryptammonium ou chlorure de 4-(4-fluorobenzoyloxy)-DPT), du chlorure de 4-(4-fluorobenzoyloxy)-DPT cristallin, du chlorure de (2-{4-[(2,2-diméthylpropanoyl)oxy]-1H-indol-3 yl}éthyl)dipropylazanium (chlorure de 4-pivaloyloxy-N,N-di-n-propyltryptammonium ou chlorure de 4-PivO-DPT), du chlorure de 4-PivO-DPT cristallin, du diméthyl({2-[4-(propanoyloxy)-1H-indol-3-yl]éthyl})azanium (2E)-3-carboxyprop-2-énoate (hydrofumarate de 4-propanoyloxy-N,N-diméthyltryptammonium ou hydrofumarate de 4-Pro-DMT), de l'hydrofumarate de 4-Pro-DMT cristallin, de l'hydrate de chlorure de (2-{4-[(4-nitrobenzènesulfonyl)oxy]-1H-indol-3-yl}éthyl)dipropylazanium (hydrate de chlorure de 4-[(4-nitrophényl)sulfonyloxy]-N,N-di-n-propyltryptammonium ou hydrate de chlorure de 4-[(4-nitrophényl)sulfonyloxy]-DPT), de l'hydrate de chlorure de 4-[(4-nitrophényl)sulfonyloxy]-DPT cristallin, et des formes cristallines spécifiques de ceux-ci, comprenant la forme cristalline 1 de chlorure de 4-(méthylsulfonyloxy)-DPT, la forme cristalline 1 de chlorure de 4-(4-trifluorométhylbenzoyloxy)-DPT, la forme cristalline 1 de chlorure de 4-(4-fluorobenzoyloxy)-DPT, la forme cristalline 1 de chlorure de 4-PivO-DPT, la forme cristalline 1 d'hydrofumarate de 4-Pro-DMT, et la forme cristalline 1 d'hydrate de chlorure de 4-[(4-nitropheényl)sulfonyloxy]-DPT ; des compositions les contenant ; et des procédés de traitement les utilisant.
PCT/US2023/078615 2022-11-04 2023-11-03 Dérivés de tryptamine WO2024097944A2 (fr)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US202263422582P 2022-11-04 2022-11-04
US63/422,582 2022-11-04
US202263383716P 2022-11-15 2022-11-15
US202263383717P 2022-11-15 2022-11-15
US202263383720P 2022-11-15 2022-11-15
US202263383719P 2022-11-15 2022-11-15
US202263383718P 2022-11-15 2022-11-15
US63/383,717 2022-11-15
US63/383,720 2022-11-15
US63/383,718 2022-11-15
US63/383,716 2022-11-15
US63/383,719 2022-11-15

Publications (2)

Publication Number Publication Date
WO2024097944A2 true WO2024097944A2 (fr) 2024-05-10
WO2024097944A3 WO2024097944A3 (fr) 2024-06-06

Family

ID=90931676

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/078615 WO2024097944A2 (fr) 2022-11-04 2023-11-03 Dérivés de tryptamine

Country Status (1)

Country Link
WO (1) WO2024097944A2 (fr)

Similar Documents

Publication Publication Date Title
AU2021397252B2 (en) Dialkyl tryptamines and their therapeutic uses
AU2022206448B2 (en) Quaternary tryptamines and their therapeutic uses
US20240158349A1 (en) Tryptamine derivatives and their therapeutic uses
AU2021273802B2 (en) Crystalline 4-hydroxy-N,N-di-n-propyltryptammonium (4-HO-DPT) salts
WO2023201293A2 (fr) Dérivés de tryptamine
AU2022365018A1 (en) Crystalline tryptamine compounds
EP4274888A1 (fr) Alkyl-tryptamines protégées et leurs utilisations thérapeutiques
WO2024097944A2 (fr) Dérivés de tryptamine
US11981637B2 (en) 4-pivaloyloxy-n-methyltryptammonium chloride
WO2024016012A2 (fr) Dérivés de tryptamine
WO2024040158A2 (fr) Dérivés de tryptamine
WO2023250465A2 (fr) Dérivés de tryptamine
WO2024026291A1 (fr) Dérivés de tryptamine quaternaire substituée par un méthyle
WO2023205768A2 (fr) Sels quaternaires cristallins de tryptamines substituées en position 4
WO2024054973A2 (fr) Dérivés de tryptamine
WO2023108167A1 (fr) Dérivés de psilocybine
WO2023225678A2 (fr) Dérivés de tryptamine
AU2022220590B2 (en) Crystalline 5-methoxy-dipropyl tryptamine compounds
WO2024073356A1 (fr) Chlorure de 2-(2-éthoxy-4-(éthylthio)-5-méthoxyphényl)éthan-1-aminium
US20230146719A1 (en) Crystalline n-methyl tryptamine derivatives
WO2023225679A2 (fr) N-isopropyl tryptamines et procede de fabrication d'analogues de tryptamine monoalkyles et dialkyles
WO2024107829A1 (fr) Dérivés cristallins de n-méthyl tryptamine